Parkinson’s News Today (12/19, Wexler) reports, “Nuplazid (pimavanserin) outperformed a placebo at managing psychosis in people with Parkinson’s disease dementia in a Phase 3 clinical trial.” This result “‘supports the maintenance of antipsychotic efficacy and safety of [Nuplazid] in patients with Parkinson’s disease dementia and psychosis,’ the researchers wrote” in Parkinsonism and Related Disorders.
Related Links:
— “Nuplazid effectively treats psychosis in Parkinson’s dementia patients,” Marisa Wexler, Parkinson’s News Today, December 19, 2023